Key Financial Results (Consolidated)

Quarterly Performance Comparison:

  • Revenue: ₹189.75 crore in Q1 FY27 vs ₹145.07 crore in Q1 FY26 (30.8% YoY growth)
  • EBITDA: ₹47.46 crore in Q1 FY27 vs ₹51.70 crore in Q1 FY26
  • EBITDA Margin: 25.0% in Q1 FY27 vs 35.6% in Q1 FY26
  • Profit After Tax (PAT): ₹24.04 crore in Q1 FY27 vs ₹34.79 crore in Q1 FY26 (30.9% decline)
  • PAT Margin: 12.7% in Q1 FY27 vs 24.0% in Q1 FY26
  • Quarterly EPS: ₹2.99 in Q1 FY27 vs ₹4.32 in Q1 FY26

Segment-wise Revenue Contribution

Therapeutic Segments (Q1 FY27):

  • Anesthetic segment: 48% of revenue (vs 53% in Q1 FY26)
  • Vitamins: 17% of revenue (vs 11% in Q1 FY26)

Geographic Revenue Distribution (Q1 FY27):

  • Asia: 39% of revenue (vs 32% in Q1 FY26)
  • Europe: 35% of revenue
  • LATAM: 20% of revenue
  • North America: 3% of revenue
  • Other markets: 3% of revenue
  • Export contribution: 81% of total revenue

Operational Highlights

Product Pipeline Updates:

  • Cardiovascular product launched in Q3 FY26 began contributing revenue in Q4 FY26, with momentum strengthening for future scale-up
  • ADHD product witnessed strong demand from LATAM and Europe and is now scaling up
  • Liquid Anesthetic product has been commercialized with steady monthly supplies underway
  • FY27 product pipeline includes plans for approximately two launches each in Anesthetic and ADHD segments

Manufacturing Capacity:

  • Capacity utilization: 70% in Q1 FY27 (vs 74% in FY26 and 70% in FY25)
  • Total reactor capacity: 932 KLPD across manufacturing blocks
  • Ambernath facility has commissioned finished dosage manufacturing capabilities covering tablets, capsules, liquids, nasal, inhalation and injections
  • Validation and registration batches underway for dossier submissions

R&D Capabilities:

  • 68+ scientists focused primarily on API and formulation process development
  • Two R&D centres started at Ambernath and Lote
  • Efforts to add 3–4 products annually

Management Commentary

Dr. Satish Wagh, Executive Chairman and Whole-Time Director, stated: "Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets. Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across Anesthetic and ADHD, we remain focused on building sustainable long-term growth."

Company Background

Supriya Lifescience Ltd. is a cGMP-compliant API manufacturer founded in 1987 with certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company has facilities in Khed, District Ratnagiri with additional certifications from WHO, PMDA, KFDA and ANVISA. The company holds eight active CEPs and fourteen active USDMFs, serving more than 120 countries globally.